secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2026-07-13T12:37:12+00:00
Accession:  0001104659-26-082902
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise completes $1.55B sale of muscular dystrophy program to Servier; up to $2.65B total
--------------------------------------------------------------------------------

- Sold sevasemten and muscular dystrophy program to Servier for $1.55B upfront plus up to $1.1B in milestones ($2.65B total).
- Company refocuses on cardiovascular pipeline: EDG-7500 (HCM), EDG-15400 (HFpEF), and EDG-003 (undisclosed).
- Upfront proceeds expected to fully fund EDG-7500 development through potential approval.
- Plans to initiate Phase 3 trial for EDG-7500 in Q4 2026 and Phase 2 trial for EDG-15400 in HFpEF.
- Core muscular dystrophy employees offered positions at Servier to ensure continuity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465926082902/0001104659-26-082902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465926082902/tm2620181d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-082902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer